CSL Akcija

CSL DSCR

Delisted·19. јун 2026.

Vrijednost Коефицијент покривености услуга дуга (DSCR) od CSL (CSL.AX) na dan 8. авг 2026. je 0,31. Prethodne godine, Коефицијент покривености услуга дуга (DSCR) je bio 0,23 — promjena od 36,51% (viši).

DSCR

0,31

YoY

36,51%

Zadnja ažuriranja:

Коефицијент покривености услуга дуга (DSCR) od CSL je 2026 0,31 . Коефицијент покривености услуга дуга (DSCR) od CSL je bio 2025 0,23 . Pad je time 36,51% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

CSL Анализа акција

Šta radi CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji CSL

Коефицијент покривености услуга дуга (DSCR) kompanije CSL iznosi 0,31 u 2026. godini.

Коефицијент покривености услуга дуга (DSCR) od CSL se promijenio sa 0,23 na 0,31, što predstavlja promjenu od 36,51%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj Коефицијент покривености услуга дуга (DSCR) CSL od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

DSCR мери способност компаније да обслужи своје обавезе по дугу из пословног дохотка. Коефицијент већи од 1,0 указује на довољан доход за покривање плаћања по дугу.

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti Коефицијент покривености услуга дуга (DSCR)'s CSL sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Access this data via the Eulerpool API

Финансијска полуга — CSL

Sve ključne metrike — CSL

Раст